Signet-ring cell carcinoma is a rare adenocarcinoma, predominantly affecting the stomach and ovaries. Primary sites elsewhere are rarer. It is recognized that there is an increased cancer risk with the diagnosis of Crohn's disease. We report a patient with Crohn's disease who was diagnosed with signet-ring cell carcinoma in the setting of a Crohn's flare. Diagnosis was made with endoscopy. Treatment included laparoscopic-assisted right hemicolectomy with ileostomy with subsequent chemotherapy as an outpatient.
Introduction
Signet-ring cell carcinoma (SRCC) is a rare adenocarcinoma of epithelial origin, accounting for less than 0.5% of all malignancies [1] . It predominantly affects the stomach, with approximately a fourth of gastric cancers attributed to SRCC. However, SRCC has been known to affect other organs, such as the prostate, ovaries, pancreas ,and large intestine to a much lesser extent [2, 3] . In addition, only a small number of cases have been reported in patients with diagnosed Crohn's disease [4] .It is generally known that inflammatory bowel disease (IBD) increases a patient's risk for developing cancer along the gastrointestinal tract (GI), though the exact mechanism is poorly understood [5] . Theories include chronic inflammation causing dysplasia, use of immunosuppressants and biologics, and manipulation of the gut flora [6] . Herein, we present a case of SRCC involving the terminal ileum with concurrent Crohn's flare.
Case Presentation
A 44-year-old female with a history of Crohn's disease was admitted for progressive fatigue, chronic abdominal pain, and bright red blood per rectum. She was prescribed rivaroxaban approximately 2 weeks prior to this encounter for left calf tenderness determined to be secondary to a deep vein thrombosis. Physical examination on admission was notable for conjunctival pallor and right lower-quadrant tenderness on palpation of the abdomen with no distension; bowel sounds were present and normoactive. There was no appreciable fluctuation in weight in the past 12 months. Initial laboratory findings included a microcytic anemia (hemoglobin 6.6 g/dL), left-shift leukocytosis (14.3 count/μL), elevated sedimentation rate (ESR 45 mm/h), and elevated C-reactive protein (CRP 6.7 mg/L). Rivaroxaban was stopped, and the patient was transfused with packed red blood cells with a goal of hemoglobin >7.0. The patient was continued on 20 mg prednisone daily for Crohn's disease management with plans to start ustekinumab. Review of medical records showed an MRI enterography performed a month before, which suggested active Crohn's disease of the terminal ileum with increased dilatation of portions of the ileum proximal to the area of active disease; no fistula or abscesses were identified. In addition, a colonoscopy performed 1 year prior to this case presentation showed a stenotic but otherwise normally appearing ileocecal valve, preventing passage of the colonoscope and full visualization of the terminal ileum. Given her presentation and previous imaging findings, her symptoms were initially attributed to a lower GI bleed in the setting of rivaroxaban use. The patient had persistent anemia despite red blood cell transfusions prompting repeat colonoscopy. On visualization of the proximal cecum and terminal ileum, an ulcerating, partially obstructing, mass-like process was identified (Fig. 1) . The mass was biopsied, which revealed SRCC with mucinous features. Additional laboratory tests included a carcinoembryonic antigen, which was within normal limits (CEA 1.8). Computed tomography of the chest, abdomen, and pelvis revealed no evidence of metastatic disease; radiographic measurement of the mass revealed approximately 8 cm in length at the distal ileum. The patient subsequently underwent laparoscopic-assisted right hemicolectomy with ileostomy, with the excised sample sent for gross pathology (Fig. 2a) . Final pathological diagnosis was poorly-differentiated signet-ring cell adenocarcinoma (T4aN1) of the terminal ileum, ileocecal valve, and cecum (Fig. 2b) . Molecular diagnostic was negative for RAS and BRAF genes. The patient was seen by medical oncology as an outpatient and was started on folinic acid, fluorouracil, and oxaliplatin (FOLFOX) adjuvant therapy.
Discussion
Cancer of the small intestine is a rare diagnosis. However, in patients with Crohn's disease, the relative risk of having a malignancy of the small intestine increases up to 30 times compared to the general population. Undoubtedly, abnormal imaging and symptom presentations should raise the specter of malignancy in individuals with IBD if the clinical context is ripe. In our patient's case, it was difficult to distinguish between malignancy and inflammation. MRI enterography has been shown to be useful in the diagnosis and management of IBD, but its role in deciphering between inflammatory flares in IBD and new malignancies continue to evolve [7, 8] . Although it is consensual knowledge that IBD increases the risk of GI malignancies, a proper modality or algorithm of screening or follow-up is not present in standard of care guidelines.
In addition, our patient had a previous colonoscopy, which showed abnormalities of the ileocecal valve most consistent with stricturing Crohn's disease. As mentioned above, inflammatory changes can be observed, but in our case, there was a quick development of malignancy between colonoscopy procedures. Such a rapidly developing entity is challenging to anticipate even with frequent procedures [9] . Given the various aggressiveness of GI malignancies that may develop in the setting of IBD, further investigation into improving the detection of malignancies early, either through more specific biomarker surveillance or increased sites of biopsy, is warranted.
Additionally, our patient was treated with the appropriate medical therapy for her Crohn's disease. Our team questioned whether the number of inflammatory flares predisposed her for her diagnosed malignancy [10] . Certainly, SRCC of the small intestine carries a rare diagnosis. In all, the current literature present neither patient studies of long-term medical therapies nor the impact of other comorbidities to prevent the development of malignancies. Though there are studies of chemoprevention of malignancy in Crohn's disease, longterm data are limited, and further investigation is needed [11] .
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